Phase i clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma Academic Article uri icon

Overview

MeSH Major

  • Epothilones
  • Tubulin Modulators

abstract

  • KOS-862 was well tolerated with manageable toxicity, favorable PK profile, and the suggestion of clinical activity. The maximum tolerated dose was determined to be 100 mg/m(2) weekly 3-on/1-off. MTBF can be demonstrated in PBMCs of patients exposed to KOS-862.

publication date

  • December 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4003559

Digital Object Identifier (DOI)

  • 10.1007/s10637-011-9765-7

PubMed ID

  • 22072399

Additional Document Info

start page

  • 2294

end page

  • 302

volume

  • 30

number

  • 6